Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADXS NASDAQ:BNTC NASDAQ:CYTO NASDAQ:ENSC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADXSAyala Pharmaceuticals$0.03$0.06$0.00▼$0.78$1.42M1.175,440 shs95 shsBNTCBenitec Biopharma$11.04-6.0%$14.01$7.05▼$17.15$308.18M0.3758,648 shs98,440 shsCYTOAltamira Therapeutics$0.30-25.9%$0.36$0.30▼$1.34$1.02M1.8289,627 shs753,013 shsENSCEnsysce Biosciences$2.13-1.4%$2.21$1.62▼$14.67$5.12M0.98955,109 shs76,623 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADXSAyala Pharmaceuticals0.00%-77.38%-72.32%+5.21%-77.80%BNTCBenitec Biopharma-5.96%-13.62%-26.10%-19.71%+13.81%CYTOAltamira Therapeutics0.00%0.00%0.00%0.00%-78.42%ENSCEnsysce Biosciences-1.39%-1.39%0.00%+21.02%-69.66%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADXSAyala PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ABNTCBenitec Biopharma1.9103 of 5 stars3.61.00.00.03.40.80.0CYTOAltamira TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AENSCEnsysce Biosciences0.4631 of 5 stars0.04.00.00.01.00.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADXSAyala Pharmaceuticals 0.00N/AN/AN/ABNTCBenitec Biopharma 3.20Buy$23.83115.88% UpsideCYTOAltamira Therapeutics 0.00N/AN/AN/AENSCEnsysce Biosciences 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest BNTC, CYTO, ENSC, and ADXS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/7/2025BNTCBenitec BiopharmaTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy5/19/2025BNTCBenitec BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.00 ➝ $28.005/15/2025BNTCBenitec BiopharmaJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$20.00 ➝ $20.00(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADXSAyala Pharmaceuticals$3.24M0.44N/AN/A($2.06) per share-0.02BNTCBenitec BiopharmaN/AN/AN/AN/A$4.68 per shareN/ACYTOAltamira Therapeutics$320K3.19N/AN/A$4.56 per share0.07ENSCEnsysce Biosciences$5.21M0.97N/AN/A$2.59 per share0.82Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADXSAyala Pharmaceuticals-$48.07M-$7.98N/A∞N/AN/AN/AN/AN/ABNTCBenitec Biopharma-$21.75M-$1.51N/AN/AN/AN/A-38.26%-35.71%9/25/2025 (Estimated)CYTOAltamira Therapeutics-$4.31MN/A0.00N/AN/AN/AN/AN/AN/AENSCEnsysce Biosciences-$7.99M-$6.54N/AN/AN/A-109.49%-192.54%-121.77%8/13/2025 (Estimated)Latest BNTC, CYTO, ENSC, and ADXS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025ENSCEnsysce Biosciences-$1.02N/AN/AN/A$0.67 millionN/A5/14/2025Q3 2025BNTCBenitec Biopharma-$0.36-$0.24+$0.12-$0.24N/AN/A5/13/2025Q1 2025ENSCEnsysce Biosciences-$3.02-$1.39+$1.63-$1.39$0.65 million$1.32 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADXSAyala PharmaceuticalsN/AN/AN/AN/AN/ABNTCBenitec BiopharmaN/AN/AN/AN/AN/ACYTOAltamira TherapeuticsN/AN/AN/AN/AN/AENSCEnsysce BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADXSAyala PharmaceuticalsN/AN/AN/ABNTCBenitec Biopharma0.0114.8014.80CYTOAltamira TherapeuticsN/A0.43N/AENSCEnsysce BiosciencesN/A2.502.50Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADXSAyala Pharmaceuticals7.18%BNTCBenitec Biopharma52.19%CYTOAltamira Therapeutics1.91%ENSCEnsysce Biosciences5.63%Insider OwnershipCompanyInsider OwnershipADXSAyala Pharmaceuticals0.63%BNTCBenitec Biopharma1.30%CYTOAltamira Therapeutics13.03%ENSCEnsysce Biosciences7.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADXSAyala Pharmaceuticals2042.63 million42.36 millionNot OptionableBNTCBenitec Biopharma2026.25 million25.91 millionNo DataCYTOAltamira Therapeutics203.40 million2.96 millionNot OptionableENSCEnsysce Biosciences102.37 million2.18 millionNot OptionableBNTC, CYTO, ENSC, and ADXS HeadlinesRecent News About These CompaniesENSC Start Phase 3 Trial on Abuse-Resistant Pain RelieverJuly 16 at 12:44 AM | finance.yahoo.comEnsysce Biosciences Initiates Pivotal Phase 3 Study of PF614 - A Next-Generation Opioid - Designed to Deliver Powerful Pain Relief and Reduce AbuseJuly 16 at 8:13 AM | accessnewswire.comAWall Street Zen Downgrades Ensysce Biosciences (NASDAQ:ENSC) to SellJuly 14, 2025 | americanbankingnews.comEnsysce Biosciences Inc News (ENSC) - Investing.comJuly 11, 2025 | investing.comEnsysce Biosciences Accelerates PF614-MPAR-102 Study with Full Enrollment of Part 2June 24, 2025 | accessnewswire.comAEnsysce Biosciences Announces Speakers for Major Symposium at PAINWeek 2025June 11, 2025 | accessnewswire.comAensysce biosciences appoints baker tilly as new auditorJune 7, 2025 | investing.comEnsysce Flat on Receiving GrantJune 4, 2025 | baystreet.caEnsysce Biosciences Awarded $5.3 Million in Continued NIDA Support to Advance Breakthrough Opioid Overdose ProtectionJune 4, 2025 | accessnewswire.comAENSC is Moving Closer to Changing the Pain Relief MarketMay 14, 2025 | finance.yahoo.comEnsysce Biosciences Shares Jump After Receiving Patent, Reporting 1Q ResultsMay 14, 2025 | marketwatch.comEnsysce Biosciences Reports First Quarter 2025 Financial ResultsMay 13, 2025 | accessnewswire.comAEnsysce Biosciences Bolsters Management Team with Regulatory ExpertMay 12, 2025 | accessnewswire.comAEnsysce Biosciences secures patent for OUD treatmentApril 25, 2025 | uk.investing.comEnsysce Biosciences receives U.S. patent for OUD treatmentApril 25, 2025 | markets.businessinsider.comEnsysce Biosciences, Inc. Announces Closing of Exercise of Warrants for $2.2 Million Gross ProceedsApril 24, 2025 | accessnewswire.comAEnsysce Biosciences, Inc. Announces Exercise of Warrants for $2.2 Million Gross ProceedsApril 23, 2025 | gurufocus.comEnsysce Biosciences Stock Doubles In One Trading Session - Here's WhyApril 23, 2025 | benzinga.comEnsysce Biosciences, Inc. Announces Exercise of Warrants for $2.2 Million Gross ProceedsApril 23, 2025 | accessnewswire.comAEnsysce Biosciences Receives U.S. Patent for Groundbreaking Treatment of Opioid Use DisorderApril 23, 2025 | accessnewswire.comANew MarketBeat Followers Over TimeMedia Sentiment Over TimeBNTC, CYTO, ENSC, and ADXS Company DescriptionsAyala Pharmaceuticals NASDAQ:ADXS$0.03 0.00 (0.00%) As of 07/18/2025Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.Benitec Biopharma NASDAQ:BNTC$11.04 -0.70 (-5.96%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$11.06 +0.02 (+0.14%) As of 07/18/2025 07:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.Altamira Therapeutics NASDAQ:CYTOAltamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland and Australia. The company develops and supplies OligoPhore/SemaPhore platforms, which are peptide-based nanoparticle technologies for ribonucleic acid delivery to extrahepatic tissues. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is developing AM-401 for the treatment of KRAS driven cancer; AM-411 for the treatment of rheumatoid arthritis; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase II/III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It also offers Bentrio, a drug-free nasal spray for protection against airborne viruses and allergens. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. The company was founded in 2003 and is based in Hamilton, Bermuda.Ensysce Biosciences NASDAQ:ENSC$2.13 -0.03 (-1.39%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$2.12 -0.01 (-0.47%) As of 07/18/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP oxycodone prodrug candidate for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF614, an extended-release oxycodone-derivative that releases clinically effective oxycodone; PF329 for pain with abuse protection; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD; and PF9001 to treat Opioid use disorder. The company was founded in 2003 and is based in La Jolla, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/14 - 07/18 Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.